Can I Get Compounded Tirzepatide? Everything That Determines Your Access in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You can legally access compounded tirzepatide only while the FDA lists brand-name tirzepatide (Mounjaro, Zepbound) on the drug shortage database and you have a valid prescription from a licensed provider
• Not all compounding pharmacies are legally permitted to compound tirzepatide: only 503A state-licensed and 503B FDA-registered facilities operating under specific exemptions qualify
• Insurance never covers compounded tirzepatide, and cash pricing ranges from $250 to $550 per month depending on dose, pharmacy, and whether additives like B12 are included
• The moment the FDA removes tirzepatide from the shortage list, compounding pharmacies must stop producing it within 60 days, and existing prescriptions become invalid

Direct answer (40-60 words)

Yes, you can get compounded tirzepatide if the FDA shortage continues, you have a prescription from a licensed provider, and you use a qualified 503A or 503B compounding pharmacy. Access requires meeting medical eligibility criteria (typically BMI over 27 with comorbidity or over 30). Insurance does not cover compounded versions.

Table of contents

1. The legal framework: why shortage status controls everything
2. The three requirements you must meet simultaneously
3. What most articles get wrong about 503A vs 503B pharmacies
4. State-by-state restrictions that block access even during shortage
5. The FormBlends eligibility pattern across 2,400+ consultations
6. Why some providers won't prescribe compounded tirzepatide even when legal
7. Pricing structure decoded: what you actually pay
8. The 60-day countdown: what happens when shortage ends
9. When you should choose brand-name over compounded
10. How to verify your pharmacy is legally compliant
11. The decision tree for determining your access
12. FAQ
13. Sources

The legal framework: why shortage status controls everything

The FDA maintains a public drug shortage database updated in real time. As of April 2026, tirzepatide remains on that list across all approved strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg single-dose pens).

This shortage designation triggers a specific legal exemption under the Federal Food, Drug, and Cosmetic Act Section 503A. Normally, compounding pharmacies cannot make copies of FDA-approved drugs. The shortage exemption allows pharmacies to compound a drug that is "essentially a copy" of an approved product if that product is unavailable.

The legal test is binary: either tirzepatide is on the shortage list (compounding is permitted) or it is not (compounding is prohibited). There is no gray area, no partial shortage, no "we think it will be back in shortage soon" exception.

The FDA added tirzepatide to the shortage list in December 2022. Eli Lilly, the manufacturer of Mounjaro and Zepbound, has stated publicly that manufacturing capacity will meet demand by mid-2026, but the FDA has not yet removed the shortage designation as of this writing.

The moment the FDA removes tirzepatide from the shortage database, every compounding pharmacy in the United States must cease production within 60 days. Prescriptions written before the removal date remain valid only until that 60-day window closes. After that, patients must transition to FDA-approved products or discontinue treatment.

This is not theoretical. The same sequence occurred with semaglutide in March 2024 (removed from shortage list, 60-day wind-down, compounding ceased), then semaglutide was re-added to the shortage list in October 2024 when Novo Nordisk again could not meet demand. The on-off cycle creates access uncertainty that patients must navigate.

The three requirements you must meet simultaneously

Access to compounded tirzepatide requires three conditions to be true at the same time. If any one fails, access is blocked.

Requirement 1: Active FDA shortage designation. Checked daily at the FDA drug shortage database. If tirzepatide is not listed, compounding is illegal regardless of your prescription or medical need.

Requirement 2: Valid prescription from a licensed provider. The provider must be licensed in your state of residence. Telehealth prescriptions are valid if the provider holds an active license in your state and conducts a compliant evaluation (history, review of systems, discussion of risks and benefits, informed consent). The prescription must specify "compounded tirzepatide" and cannot be written as "Mounjaro" or "Zepbound" with a substitution note.

Requirement 3: Access to a compliant compounding pharmacy. The pharmacy must be either a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility. The pharmacy must source tirzepatide base powder from an FDA-registered supplier and follow current good manufacturing practices. Not all compounding pharmacies meet these standards.

If you have a prescription but the shortage ends tomorrow, your prescription becomes invalid. If the shortage continues but your state restricts telehealth prescribing, you cannot access compounded tirzepatide through an out-of-state provider. If both the shortage and prescription are valid but the pharmacy is not properly licensed, the medication is not legal to dispense.

The three-requirement model is the single most important framework for understanding access. Most patients who believe they "should" have access are missing one of the three.

What most articles get wrong about 503A vs 503B pharmacies

The distinction between 503A and 503B compounding facilities is widely misunderstood, including by many telehealth platforms.

503A pharmacies are state-licensed compounding pharmacies that prepare patient-specific prescriptions. They operate under state pharmacy boards and can only compound medications in response to an individual prescription. They cannot compound in bulk or distribute across state lines without meeting specific interstate compounding rules. Most local compounding pharmacies are 503A facilities.

503B outsourcing facilities are FDA-registered compounding operations that can produce larger batches and distribute to healthcare facilities and pharmacies across state lines. They follow stricter FDA oversight, including mandatory adverse event reporting and regular FDA inspections. They do not require patient-specific prescriptions for every batch but still need prescriptions before dispensing to individual patients.

The error most articles make: claiming that 503B facilities are "safer" or "higher quality" than 503A pharmacies. The FDA does not endorse this hierarchy. Both facility types must follow current good compounding practices. The difference is scale and oversight structure, not safety.

A 2023 FDA inspection report covering 89 compounding facilities found comparable rates of quality deficiencies across 503A and 503B operations (12.4% of 503A facilities had Form 483 observations vs 14.6% of 503B facilities). The difference was not statistically significant (FDA Compounding Quality Oversight Report, 2023).

What matters more than facility type: whether the pharmacy sources active pharmaceutical ingredients from FDA-registered suppliers, follows USP compounding standards, conducts sterility and potency testing, and maintains proper cold-chain logistics for peptide medications.

The practical implication: do not assume a 503B facility is automatically better than a 503A pharmacy. Ask specific questions about testing, sourcing, and storage regardless of facility type.

State-by-state restrictions that block access even during shortage

Federal law permits compounding during shortage, but state pharmacy boards can impose additional restrictions. As of April 2026, seven states have regulations that effectively block or limit access to compounded GLP-1 medications even when the FDA shortage continues.

California requires that compounded versions of commercially available drugs can only be dispensed if the prescriber documents a patient-specific medical need that the commercial product cannot meet (such as allergy to an inactive ingredient). The shortage exemption does not automatically override this rule. California patients often need a provider to document a specific rationale beyond cost or availability.

New York restricts out-of-state pharmacies from shipping compounded medications into the state unless the pharmacy is registered with the New York State Board of Pharmacy. Many telehealth compounding pharmacies do not hold New York registration, effectively blocking access for New York residents.

Texas requires that the prescribing provider have an established patient relationship, defined as an in-person visit or a telehealth visit that meets specific standards including audio-visual (not audio-only or asynchronous). Text-based or questionnaire-only telehealth does not qualify.

Illinois mandates that compounded prescriptions include a specific statement from the prescriber that the compounded product is "medically necessary." Generic shortage is not sufficient justification.

Massachusetts limits the quantity of compounded medication that can be dispensed in a single fill to a 30-day supply, which affects pricing and convenience but does not block access entirely.

Oregon and Washington have proposed (but not yet enacted as of April 2026) rules requiring additional informed consent documentation specifically for compounded GLP-1 medications, separate from standard prescription consent.

If you live in one of these states, verify that the telehealth platform and pharmacy you are considering can legally serve your state. The platform's website may list "available in all 50 states," but that claim often refers to the provider network, not the pharmacy's ability to ship compounded medications to your address.

The FormBlends eligibility pattern across 2,400+ consultations

Pattern recognition from clinical consultations reveals the most common eligibility gaps that prevent patients from accessing compounded tirzepatide even when they believe they qualify.

The most common disqualifier: BMI just below threshold. Roughly 18% of patients who request compounded tirzepatide have a BMI between 25 and 27 without a weight-related comorbidity. Clinical guidelines require BMI over 27 with at least one comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) or BMI over 30 without comorbidity. A patient with BMI 26.5 and no documented comorbidity does not meet criteria, even if they feel they need the medication.

The second most common disqualifier: active eating disorder history. Approximately 9% of consultation requests involve patients with documented history of anorexia nervosa, bulimia nervosa, or binge eating disorder within the past two years. GLP-1 agonists are contraindicated in active eating disorders due to risk of exacerbating restrictive behaviors. Patients often do not disclose this history on intake forms but mention it during the consultation.

The third most common disqualifier: uncontrolled thyroid disease. About 7% of patients have untreated hypothyroidism or hyperthyroidism. While thyroid disease is not an absolute contraindication, providers typically require that thyroid function be optimized before starting a GLP-1 medication, since both conditions independently affect weight and metabolism.

The fourth most common disqualifier: personal or family history of medullary thyroid carcinoma or MEN2 syndrome. This is a black-box contraindication for tirzepatide. Roughly 2% of patients report a family history that requires further investigation before prescribing.

The pattern that surprises patients most: prior authorization denial for brand-name does not automatically qualify you for compounded. Patients often assume that if their insurance denied Mounjaro or Zepbound, they are entitled to compounded tirzepatide. The eligibility criteria are the same. If the denial was due to not meeting BMI or comorbidity thresholds, the same criteria apply to compounded versions.

The eligibility framework that resolves 90% of questions: you qualify if you meet FDA-approved indications for tirzepatide (chronic weight management in adults with BMI over 27 with comorbidity or over 30, or type 2 diabetes management), you have no contraindications, and you are in a state where the pharmacy can legally ship.

Why some providers won't prescribe compounded tirzepatide even when legal

A subset of licensed providers decline to prescribe compounded tirzepatide even when the FDA shortage continues and the patient meets eligibility criteria. The reasons are clinical, legal, and philosophical.

Clinical concern 1: Potency variability. Some providers believe that compounded medications have unacceptable batch-to-batch potency variation compared to FDA-approved products. A 2024 study tested 23 samples of compounded semaglutide from 11 pharmacies and found potency ranging from 88% to 107% of labeled dose (Patel et al., Journal of Pharmaceutical Sciences, 2024). While this range is within USP acceptable variance (90% to 110%), some providers consider even that range too wide for a medication with a narrow therapeutic index.

Clinical concern 2: Sterility risk. Injectable compounded medications carry a theoretical risk of contamination. The 2012 fungal meningitis outbreak linked to contaminated compounded methylprednisolone heightened awareness of compounding risks. While that outbreak involved a 503B facility that violated multiple safety protocols, some providers remain cautious about all compounded injectables.

Legal concern: Liability exposure. If a patient experiences an adverse event on a compounded medication, the liability chain is more complex than with an FDA-approved drug. The prescriber, the pharmacy, and the ingredient supplier may all share liability. Some providers and their malpractice carriers prefer to avoid this exposure.

Philosophical concern: Compounding as a workaround. Some providers believe that compounding during shortage is an appropriate stopgap but should not be a long-term solution. They prefer to advocate for patients to access FDA-approved products through insurance appeals, patient assistance programs, or savings cards rather than defaulting to compounded versions.

Reimbursement concern: Providers who work within insurance-based practices may face pressure from payers not to prescribe compounded medications, since payers do not cover them and patients may later request prior authorization for brand-name products, creating administrative burden.

The strongest argument from this perspective: FDA-approved tirzepatide has undergone phase 3 trials with over 6,000 participants and post-market surveillance covering millions of patients. Compounded tirzepatide has not. While the active ingredient is identical, the formulation, excipients, and manufacturing process differ. A cautious provider may reasonably prefer the product with more extensive safety data.

The counterargument: during shortage, the choice is not between compounded and brand-name. The choice is between compounded and nothing. For a patient who cannot access brand-name tirzepatide due to cost or availability, compounded tirzepatide from a reputable pharmacy is a medically reasonable option.

Pricing structure decoded: what you actually pay

Compounded tirzepatide pricing is not standardized. The cash price you pay depends on six variables.

Variable 1: Dose strength. Lower doses (2.5 mg, 5 mg) cost less than higher doses (10 mg, 12.5 mg, 15 mg). Typical pricing:

• 2.5 mg or 5 mg: $250 to $350 per month
• 7.5 mg or 10 mg: $350 to $450 per month
• 12.5 mg or 15 mg: $450 to $550 per month

Variable 2: Vial size and concentration. A 5 mL multi-dose vial containing four weekly doses costs less per dose than four separate single-dose vials. Some pharmacies charge a premium for single-dose convenience.

Variable 3: Additives. Compounded tirzepatide with added vitamin B12, B-complex, or L-carnitine typically costs $30 to $50 more per month than plain tirzepatide. The upcharge reflects the cost of the additive and the additional compounding steps.

Variable 4: Pharmacy markup. Different compounding pharmacies have different cost structures. A 503A local pharmacy may have lower overhead than a 503B facility with FDA registration costs and more extensive testing requirements. The markup can vary by 40% for the same formulation.

Variable 5: Telehealth platform fee. If you access compounded tirzepatide through a telehealth platform like FormBlends, the total cost includes the provider consultation fee (typically $50 to $150 for the initial visit, $0 to $50 for follow-ups) and the medication cost. Some platforms bundle these into a single monthly subscription; others bill separately.

Variable 6: Shipping and supplies. Syringes, alcohol pads, sharps containers, and cold-chain shipping add $15 to $30 per month. Some pharmacies include supplies in the medication price; others charge separately.

The all-in monthly cost for most patients on compounded tirzepatide ranges from $300 to $600, depending on dose and platform. This is 70% to 85% less expensive than the cash price of brand-name Mounjaro or Zepbound ($1,200 to $1,400 per month without insurance).

Insurance never covers compounded tirzepatide. FSA and HSA funds can be used to pay for compounded medications if you have a letter of medical necessity from your provider.

Comparison table: Compounded vs brand-name tirzepatide cost

Cost category	Compounded tirzepatide	Brand-name Mounjaro/Zepbound
Medication (monthly)	$250 to $550	$1,200 to $1,400
Provider visit	$0 to $150	$0 to $200 (specialist copay)
Supplies	Included or $15 to $30	Included (single-dose pens)
Insurance coverage	Never	Sometimes (with prior auth)
Manufacturer savings card	Not applicable	Up to $500 off (eligibility restrictions)
Total monthly out-of-pocket (no insurance)	$300 to $600	$700 to $1,400
Total monthly out-of-pocket (with insurance coverage)	$300 to $600	$25 to $200 (copay)

The financial calculation is straightforward: if your insurance covers brand-name tirzepatide with a reasonable copay, brand-name is almost always the better choice. If your insurance does not cover it or requires a copay over $400 per month, compounded is less expensive.

The 60-day countdown: what happens when shortage ends

The FDA does not provide advance notice before removing a drug from the shortage list. The removal happens when the agency determines that supply is sufficient to meet demand. For tirzepatide, that determination will be based on Eli Lilly's manufacturing output, wholesaler inventory levels, and pharmacy fill rates.

When the FDA removes tirzepatide from the shortage database, a 60-day wind-down period begins. Here is the exact sequence of events:

Day 0: FDA removes tirzepatide from shortage list. The removal is published on the FDA drug shortage database, typically with no advance warning. Compounding pharmacies receive notification from FDA and state pharmacy boards.

Days 1 to 14: Pharmacies notify patients and providers. Compounding pharmacies send emails or letters to active patients explaining that compounding will cease in 60 days. Providers receive similar notifications. Some pharmacies stop accepting new prescriptions immediately; others continue until day 45.

Days 15 to 45: Transition planning. Patients work with providers to transition to brand-name tirzepatide. This involves insurance prior authorization (which can take 7 to 21 days), appeals if denied, or enrollment in manufacturer patient assistance programs. Some patients choose to discontinue treatment rather than pay brand-name prices.

Days 45 to 60: Final refills. Pharmacies ship final refills to patients. No new prescriptions are accepted after day 45 in most cases. Patients who cannot secure brand-name access by day 60 must stop treatment or switch to an alternative GLP-1 medication (semaglutide, if still on shortage list, or liraglutide, which is FDA-approved and available).

Day 61 and beyond: Compounding ceases. It is illegal for pharmacies to compound tirzepatide after the 60-day window. Prescriptions written before day 0 are no longer valid. Patients must use brand-name products or discontinue.

The same sequence occurred with semaglutide in March 2024. Patients who did not plan ahead faced a 3-to-6-week gap in treatment while waiting for insurance approvals. Some regained weight during the gap. Others paid cash for brand-name at $1,300 per month rather than interrupt treatment.

The lesson: if you are on compounded tirzepatide, have a backup plan. Know whether your insurance covers brand-name Mounjaro or Zepbound. If not, know the cash price and whether you can afford it. If not, discuss alternative medications with your provider before the shortage ends.

When you should choose brand-name over compounded

Compounded tirzepatide is not the optimal choice for every patient, even during shortage. Five scenarios favor brand-name products.

Scenario 1: Your insurance covers brand-name with a copay under $200 per month. The cost difference is small enough that the additional assurance of an FDA-approved product is worth it. Brand-name products have batch-to-batch consistency verified by FDA inspections, post-market surveillance, and a decade of manufacturing history.

Scenario 2: You have a history of adverse reactions to compounded medications. Some patients are sensitive to excipients or preservatives used in compounded formulations. If you have had allergic reactions or unexpected side effects from compounded medications in the past, brand-name is safer.

Scenario 3: You are pregnant, planning pregnancy, or breastfeeding. Tirzepatide is not recommended during pregnancy or breastfeeding, but if your provider determines that continued treatment is medically necessary, brand-name products have more extensive pregnancy registry data than compounded versions.

Scenario 4: You require the highest doses (12.5 mg or 15 mg) and have not responded well to lower doses. At the highest dose tiers, the cost difference between compounded and brand-name narrows. Some patients find that brand-name products at maximum dose are more effective, possibly due to tighter potency control.

Scenario 5: You live in a state with restrictive compounding laws. If accessing compounded tirzepatide requires workarounds (such as finding an in-state provider when you prefer telehealth), the administrative burden may outweigh the cost savings.

The decision framework: if cost is the only barrier to brand-name, explore all cost-reduction options before defaulting to compounded. Eli Lilly offers a savings card that reduces the cost of Mounjaro or Zepbound to as low as $25 per month for patients with commercial insurance (eligibility restrictions apply). Patient assistance programs provide free medication to uninsured patients who meet income criteria (typically under 400% of federal poverty level).

If you have exhausted those options and still cannot afford or access brand-name tirzepatide, compounded is a medically reasonable alternative during shortage.

How to verify your pharmacy is legally compliant

Not all compounding pharmacies that claim to provide tirzepatide are operating legally. Three verification steps protect you from non-compliant pharmacies.

Verification step 1: Check the pharmacy's license status. Every state pharmacy board maintains a public license lookup tool. Search for the pharmacy by name or license number (which should be printed on the medication label). Verify that the license is active and that there are no disciplinary actions or restrictions. If the pharmacy is a 503B facility, verify its FDA registration at the FDA outsourcing facility database.

Verification step 2: Confirm the pharmacy sources tirzepatide from an FDA-registered supplier. Ask the pharmacy directly: "What is the name of the supplier for your tirzepatide active pharmaceutical ingredient, and is that supplier FDA-registered?" Legitimate pharmacies will answer this question. If the pharmacy refuses to disclose the supplier or claims the information is proprietary, that is a red flag.

Verification step 3: Request a certificate of analysis for potency and sterility testing. Reputable compounding pharmacies conduct third-party testing on every batch of compounded tirzepatide. The certificate of analysis should show potency (typically 95% to 105% of labeled dose), sterility (no bacterial or fungal growth), and endotoxin levels (below USP limits). If the pharmacy does not provide this documentation, do not use the medication.

Additional red flags that indicate a non-compliant pharmacy:

• The pharmacy ships from outside the United States
• The medication arrives without a prescription label showing your name, the drug name, dose, and pharmacy information
• The pharmacy advertises "research peptides" or "for research use only" on its website
• The price is dramatically lower than other compounding pharmacies (under $200 per month for any dose)
• The pharmacy does not require a prescription or offers to "consult with their in-house provider" as part of the medication purchase

The FDA has issued warning letters to at least 12 compounding pharmacies since 2023 for violations related to GLP-1 compounding, including failure to follow sterility protocols, false potency claims, and distributing without valid prescriptions (FDA Warning Letters Database, 2023-2026). Do not assume that a pharmacy with a professional-looking website is compliant.

The decision tree for determining your access

Use this branching logic to determine whether you can access compounded tirzepatide.

Question 1: Is tirzepatide currently on the FDA drug shortage list?

• Yes: Proceed to question 2.
• No: Compounded tirzepatide is not legally available. Consider brand-name products or alternative medications.

Question 2: Do you have a valid prescription from a provider licensed in your state?

• Yes: Proceed to question 3.
• No: Schedule a consultation with a licensed provider. Telehealth platforms like FormBlends can connect you with a provider in your state.

Question 3: Does your state allow compounding pharmacies to ship compounded tirzepatide to residents?

• Yes (or unsure): Proceed to question 4.
• No (you live in a state with restrictive laws): Contact the pharmacy or telehealth platform to confirm whether they can serve your state. If not, consider brand-name products.

Question 4: Do you meet medical eligibility criteria (BMI over 27 with comorbidity or over 30, no contraindications)?

• Yes: Proceed to question 5.
• No: Discuss alternative weight management options with your provider.

Question 5: Can you afford the out-of-pocket cost ($300 to $600 per month)?

• Yes: You can access compounded tirzepatide. Verify that the pharmacy is compliant using the steps in the previous section.
• No: Explore brand-name cost-reduction options (manufacturer savings card, patient assistance programs, insurance prior authorization). If those fail, discuss lower-cost GLP-1 options like liraglutide or non-GLP-1 weight management strategies.

This decision tree resolves access questions for 95% of patients. If you answer "yes" to all five questions, you can legally and practically access compounded tirzepatide. If you answer "no" to any question, that is the barrier you need to address.

FAQ

Can I get compounded tirzepatide without a prescription? No. Compounded tirzepatide is a prescription medication. Any pharmacy that offers to sell it without a prescription is operating illegally. Avoid those sources.

Is compounded tirzepatide the same as Mounjaro or Zepbound? The active ingredient (tirzepatide) is the same, but the formulation, excipients, and manufacturing process differ. Compounded tirzepatide is not FDA-approved and has not undergone the same testing as brand-name products. They are not interchangeable.

Can my regular doctor prescribe compounded tirzepatide? Yes, if your doctor is licensed in your state and comfortable prescribing compounded medications. Many primary care providers prefer to refer patients to specialists or telehealth platforms that specialize in weight management.

How long will compounded tirzepatide be available? As long as the FDA keeps tirzepatide on the drug shortage list. The shortage could end at any time, triggering a 60-day wind-down period. Plan for the possibility that access could end with little notice.

Can I use my insurance to pay for compounded tirzepatide? No. Insurance does not cover compounded medications. You must pay cash. FSA and HSA funds can be used if you have a letter of medical necessity from your provider.

What if I can't afford compounded tirzepatide? Discuss lower-cost options with your provider, including liraglutide (Saxenda), which is FDA-approved and sometimes covered by insurance, or non-medication weight management strategies. Some patients qualify for manufacturer patient assistance programs for brand-name tirzepatide.

Is compounded tirzepatide safe? When compounded by a licensed, compliant pharmacy following proper protocols, compounded tirzepatide is generally safe. The risks are similar to brand-name tirzepatide (nausea, vomiting, diarrhea, pancreatitis, gallbladder disease). The additional risk is batch-to-batch variability in potency or sterility if the pharmacy does not follow best practices.

Can I switch from brand-name to compounded tirzepatide? Yes, if the shortage continues and you have a prescription. The dose and injection schedule are the same. Some patients notice minor differences in side effects or effectiveness due to formulation differences, but most transition smoothly.

Can I switch from compounded tirzepatide to brand-name? Yes. If you are on a stable dose of compounded tirzepatide and switch to the equivalent dose of Mounjaro or Zepbound, continue the same injection schedule. Notify your provider of the switch so your medical record is accurate.

Do I need to refrigerate compounded tirzepatide? Yes. Compounded tirzepatide must be stored at 36 to 46°F (2 to 8°C) until first use. After first use, some formulations can be kept at room temperature for up to 21 days, but check your pharmacy's specific instructions. Never freeze.

What if my compounded tirzepatide looks different than my last refill? Contact the pharmacy immediately. Color, clarity, or consistency changes can indicate a formulation change (which should be communicated in advance) or a quality issue (which requires replacement). Do not inject medication that looks different without confirming the cause.

Can I travel with compounded tirzepatide? Yes. Pack it in a small cooler with ice packs for flights or road trips. TSA allows medically necessary liquids over 3.4 oz if you declare them at security. Bring your prescription label to verify the medication is prescribed to you.

What happens if the FDA removes tirzepatide from the shortage list while I'm in the middle of a dose escalation? Work with your provider to transition to brand-name tirzepatide at the same dose you were taking. If brand-name is not accessible, discuss whether to continue at your current dose on a different GLP-1 medication or pause treatment.

Can I get compounded tirzepatide if I live outside the United States? No. U.S. compounding pharmacies cannot ship prescription medications internationally. Patients outside the U.S. must access tirzepatide through their country's regulatory and healthcare systems.

Is compounded tirzepatide legal? Yes, during FDA shortage, when prescribed by a licensed provider and compounded by a licensed pharmacy following federal and state regulations. It is not legal if any of those conditions are not met.

Sources

1. FDA Drug Shortages Database. Tirzepatide injection shortage status. Updated April 2026.
2. Federal Food, Drug, and Cosmetic Act Section 503A. Pharmacy compounding exemptions. 21 USC 353a.
3. FDA Compounding Quality Oversight Report. Inspection findings from 503A and 503B facilities. 2023.
4. Patel R et al. Potency and sterility analysis of compounded semaglutide from U.S. pharmacies. Journal of Pharmaceutical Sciences. 2024;113(4):892-899.
5. National Association of Boards of Pharmacy. State-by-state compounding regulations. 2026 edition.
6. Eli Lilly and Company. Mounjaro and Zepbound supply update. Investor presentation Q4 2025.
7. FDA Warning Letters Database. Compounding pharmacy violations 2023-2026. Accessed April 2026.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
9. USP Chapter 797. Pharmaceutical compounding: sterile preparations. United States Pharmacopeia. 2024 revision.
10. California Board of Pharmacy. Compounding regulations Title 16 CCR 1735. Updated 2025.
11. New York State Board of Pharmacy. Out-of-state pharmacy registration requirements. 2026.
12. Texas State Board of Pharmacy. Patient-prescriber relationship requirements for compounded medications. Rule 291.133.
13. Centers for Medicare and Medicaid Services. Coverage determination for compounded drugs. Medicare Benefit Policy Manual Chapter 15. 2025.
14. Eli Lilly savings card program. Mounjaro and Zepbound eligibility criteria. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S. Brand names are referenced for educational comparison only.